Loading stock data…
CAMP4 THERAPEUTICS CORPORATION (CAMP)
$3.16+0.15 (+4.98%)
Market ClosedLast close Jul 24
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CAMP in the Healthcare sector is trading at $3.16 with a market capitalization of $207M. Wall Street consensus targets $8.58 (6 analysts), implying a +171.6% move over the next 12 months. The stock is currently 59% below its 52-week high of $7.75, remaining 28.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 26 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +171.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 26) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.29M↑ | $348,000↓ | $795,000↓ | $1.50M↑ | $858,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$13.07M↓ | -$12.78M↑ | -$13.16M↓ | -$13.03M↑ | -$13.10M |
| Net Income | -$18.33M↑ | -$40.28M↓ | -$15.10M↓ | -$12.59M↓ | -$12.43M |
Peer Comparison
JNJUNHPFE
Fundamentals
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$206.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.27%
Volume
Today's trading volume
169,582
Recent News
New Strong Sell Stocks for July 16th
AYTU, CAMP and CRC have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2026.
Is CAMP4 THERAPEUTICS CORPORATION (CAMP) Stock Undervalued Ahead of Key CMP-002 Clinical Development Milestones?
We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. CAMP4 THERAPEUTICS CORPORATION (NASDAQ:CAMP) is one of the best up and coming stocks on our list. TheFly reported on June 16 that JPMorgan upgraded CAMP4 to Overweight from Neutral and increased its price target to $9 from $5. The […]
Here's Why We're Not Too Worried About Camp4 Therapeutics' (NASDAQ:CAMP) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Camp4 Therapeutics...
CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates
CAMP4 Therapeutics Corporation (CAMP) delivered earnings and revenue surprises of -49.53% and -22.19%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
CAMP4 Therapeutics Unveils Gene-Upregulation ASO Platform, Targets SYNGAP1 Clinic Entry in 2H
CAMP4 Therapeutics (NASDAQ:CAMP) outlined its approach to upregulating gene expression using antisense oligonucleotides (ASOs) and provided an update on its lead central nervous system (CNS) program targeting SYNGAP1-related disorder during a presentation at the 25th Annual Needham Healthcare Confer